CJC-1295 — Long-Acting GHRH Analog

Pharmaceutical Form: Injectable Peptide | Family: Growth Hormone Releasing Hormone (GHRH) Analogs

Presentation

Each 2ml multi-dose vial contains 2mg/vial, with Keifei® wording imprinted on the side. Vials feature an orange flip-off cap stamped with Keifei®. Supplied as:

• 10 × 2mg vials + 10 × 2ml bacteriostatic water ampoules, packed in a plastic insert inside a white & orange box.
• Each tray includes a 10-digit authentication code for originality verification.

About CJC-1295

CJC-1295 is a long-acting analog of growth hormone releasing hormone (GHRH), designed to overcome the limitations of natural GHRH’s very short half-life. GHRH is a 44-amino acid peptide hormone produced in the hypothalamus that stimulates the release of growth hormone (GH) from the pituitary gland in a pulsatile manner and also promotes slow-wave sleep.

Limitations of Natural GHRH

The active portion of GHRH (known as GHRH1-29) has a natural half-life of only ~7 minutes, primarily due to enzymatic degradation by DPP-IV, which cleaves the Tyr-Ala positions, rendering the peptide inactive. This limits its therapeutic effectiveness.

Why CJC-1295 is Different

• Engineered with substitutions at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, Leu) for improved stability and activity.
• Prevents DPP-IV cleavage and reduces peptide degradation.
• Utilizes Drug Affinity Complex (DAC) technology to covalently bind to albumin, extending half-life.
• Half-life extended from ~7 minutes to more than 7 days.

Mechanism of Bioconjugation

CJC-1295 uses bioconjugation technology to attach a reactive group to albumin in the blood. Albumin, abundant in the human body, stabilizes the peptide by preventing enzymatic degradation and rapid kidney excretion. Studies show that more than 90% of CJC-1295 remains stable after subcutaneous injection with virtually no DPP-IV degradation observed.

Benefits

• Extended GH release with less frequent dosing.
• Enhanced bioavailability and stability.
• Supports muscle growth, recovery, and improved body composition.
• Potential to improve sleep quality (slow-wave sleep).

Note: CJC-1295 is a research peptide. It should only be used under professional supervision and in compliance with local regulations.